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Abstract
Erosive lichen planus is characterized by painful, multi-focal erythematous-ulcerative areas affecting 
mucosal oral and genital areas. Topical therapies are usually ineffective, whereas systemic steroids and 
immunosuppressive agents are
frequently associated with a wide spectrum of side effects. Herein, we presented our positive experience in 
the treatment of a case of multi-resistant erosive lichen planus with extracorporeal photochemotherapy.
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Introduction
Erosive lichen planus (LP)  is  a  severe,  recurrent  and recalcitrant  disease that  affects  mucosal  oral  and 
genital areas (1–3). The cause is unknown, even if it is believed to result from an abnormal T-cell-mediated 
immune response  in  which  basal  epithelial  cells  are  recognized as  foreign  because  of  changes  in  the 
antigenicity  of  their  surface  (4).  This  condition,  characterized  by  painful,  multi-focal  erythematous-
ulcerative  areas  that  migrate  over  time,  is  often distressing  for  the patient,  interfering  with daily  life. 
Topical  therapies  (high-potency corticosteroids,  cyclosporin or tacrolimus)  are  usually  ineffective  (5–7), 
whereas long-term systemic steroids and immunosuppressive agents such as azathioprine or methotrexate 
are frequently associated with a wide spectrum of side effects (8–10).
Herein, we present our positive experience in the treatment of a case of multi-resistant erosive LP with 
extracorporeal photochemotherapy (ECP).
Case report
A 50-year-old woman was referred to our institution with painful, erythemato-ulcerative lesions involving 
both the oral and the genital mucosa; the patient also presented erythemato-cyanematous lesions on the 
trunk overlayed by vesicles and crusts (Figure 1A, C and E). 
Histology confirmed the clinical diagnosis of OLP. All routine blood, immunological and radiological tests 
were within the normal range and markers for hepatitis B and C and for HIV were negative.
The patient underwent systemic therapy with high-dose prednisone without benefit. Cyclosporin A (CyA) 
treatment was started at a dose of 3 mg/kg per day, but was discontinued after 2 weeks due to serious side 
effects.
Because of the failure of these traditional therapies we started treatment with ECP, on the basis of the 
protocol used in our department for cutaneous T-cell lymphomas, inflammatory erythroderma and graft-
versus-host disease. ECP was performed on 2 consecutive days every 3 weeks. Therapy was well tolerated, 
without infectious complications or induced lymphopenia. 
After a few weeks we observed an improvement of both cutaneous and mucosal lesions. After 16 courses 
(8 months), the patient achieved complete remission of skin lesions, with substantial re-epithelization of 
vulvar erosions as well as those located on the tongue, cheeks and lips (Figure 1B, D and F).
Discussion
High-potency topical corticosteroids represent the first-line therapy in LP, whereas topical cyclosporin or 
tacrolimus  have  been  proposed  as  second-line  treatment  for  refractory  patients.  Long-term  systemic 
steroids are usually effective, even if associated with a well-known spectrum of side effects and relapses 
following steroid withdrawal (11). Data about the efficacy of other therapeutic agents proposed in the 
treatment  of  LP,  such  as  azathioprine  or  thalidomide,  are  limited  and  controversial  (12,13).  Recently, 
methotrexate has been proposed in the treatment of patients with erosive, treatment-refractory disease, 
with encouraging results (10).
Moreover, even non-pharmacologic agents such as psoralen-UVA have been tested in LP (14). In particular, 
the effectiveness of ECP in the treatment of erosive LP is reported, to date, in four studies, concerning 25 
patients;  in  14  of  those,  as  well  as  in  our  case,  the  erosive  lesions  involved  genital  or  anal  mucosa 
(11,15,16). ECP treatment is based on the re-infusion of mononuclear cells, isolated by apheresis, after 
exposure to 8-methoxypsoralen and UVA. The mechanism underlying the efficacy of this treatment is not 
yet well characterized, but it has been hypothesized that ECP can induce a reduction in peripheral blood T-
lymphocyte subsets. The use of ECP in the treatment of LP has been proposed on the basis of the clinical 
benefit raised by GvHD patients; LP shows, in fact, several clinical and physiopathological similarities with 
lichenoid GvHD.
ECP is a relatively safe treatment, and the risk of opportunistic infections in the treated patients is low. 
However, ECP is expensive and time-consuming, and its effect is only palliative; remission depended on a 
persistent treatment with spaced sessions. In the series reported by Guyot et al. (11), only one out of the 
eight  patients  with  a  complete  response  maintained  a  stable  response  for  several  years  after  ECP 
discontinuation; others relapsed in a median time of 8.3 months. Similarly, only one out of the four patients 
described by  Kunte  et  al.  (15)  was  in  complete  remission  after  9  months.  Our  experience  about  the 
treatment of LP with ECP is positive, even if limited to a single case. Our patient, who suffered from a 
severe and multi-resistant disease, achieved a substantial response with limited side effects after a small 
number of ECP courses.  ECP treatment  permitted a  reduction in corticosteroid dosage,  such as  in  the 
majority of literature cases, even if only Bécherel  et al. (17) reported a suspension of all  other current 
treatments.  So,  in our opinion, ECP should be considered as a therapeutic option for the treatment of 
multi-resistant LP cases, even if further studies with a long-term follow-up are required in order to clarify 
the effective clinical and cost-benefit advantages.
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Figure 1. Mucosal and cutaneous lesions before (A, C, E) and after (B, D, F) eight sessions of extracorporeal 
photochemotherapy.
